References in periodicals archive ?
Nevro (NVRO) announced that the district court, in its patent dispute with Boston Scientific (BSX), issued an order on claim construction and summary judgment.
* Nevro Corp.(NASDAQ: NVRO) gained 19.3% to $75.59 as the company reported narrower than expected loss on Thursday.
William Blair analyst Margaret Kaczor says the summary judgement issued yesterday is not as bad as it seems for Nevro (NVRO).
(NYSE: NVRO) has received CE Mark for expanded MR-conditional labeling.
Leerink analyst Danielle Antalffy is defending Nevro (NVRO) shares after a 26% selloff in response to a summary judgment ruling in which either the company's patents were ruled invalid or Boston Scientific (BSX) was ruled to not infringe.
JPMorgan analyst Robbie Marcus views yesterday's selloff in shares of Nevro (NVRO) as a "clear buying opportunity." The headlines suggest Boston Scientific (BSX) was the clear winner in the summary judgment, but the "nuance in the actual ruling swings this in favor of Nevro," Marcus tells investors in a research note.
(NYSE: NVRO) has received a letter from the US Food and Drug Administration informing the company of the approvability of its Premarket Approval Application for the Senza spinal cord stimulation system, the company said on Friday.
Shares of Nevro (NVRO) are sharply lower in afternoon trading after a judge in the U.S.
(NYSE: NVRO) said it achieved record revenue of USD 8.7m in 3Q14, for an increase of 40% over the same period of the prior year.
Wells Fargo analyst Larry Biegelsen notes that last week, a contentious hearing was held in the Northern District of California in the litigation where Nevro (NVRO) is asserting that Boston Scientific (BSX) infringes seven patents related to high-frequency stimulation.
Acronyms browser ?
Full browser ?
- NVR Incorporated